Pillar · Biotech Investing
Biotech Due Diligence Checklist: How to Evaluate a Drug Pipeline and Probability of Approval
Most biotech investors skip due diligence and pay the price. This step-by-step checklist walks you through everything yo...
Start here
Pillar · Clinical Readouts
How to Read Biotech Clinical Trial Data: Phase 1, 2, 3 Results Explained for Investors
Clinical trial data is the single most important factor in biotech investing, but most investors struggle to read it. Th...
FDA & PDUFA Calendar
SION-451 Cystic Fibrosis Risk: Catalysts Aug 24
As of August 24, 2026, several biotech catalysts are set to shape the market landscape, with key dates approaching for critical drug approvals....
Clinical Readouts
MNOV MN-166 ALS Readout: Phase 3 Watch Aug 17
As of August 2026, we analyze critical phase 3 readouts and their implications for biotech investors focusing on MNOV, CMPX, and more....
FDA & PDUFA Calendar
TENX TNX-103 for PH-HFpEF: Catalysts Aug 17 2026
On August 29, 2026, Tenax Therapeutics' TNX-103 could reshape treatment for PH-HFpEF. Get insights on biotech catalysts to watch this month....
FDA & PDUFA Calendar
Capricor Deramiocel Decision: Catalysts Aug 10 2026
As we approach August 2026, several biotech catalysts are set to shape the market landscape, including CAPR's Deramiocel on August 22....
Clinical Readouts
MN-001 Diabetes Readout: Phase 2 and 3 Watch Aug 3
On August 5, 2026, we analyze pivotal phase 3 readouts, including MN-166 and CTX-009. Investors need to track these clinical trial results closely....
FDA & PDUFA Calendar
MapLight ML-007 Schizophrenia: Catalysts Aug 3 2026
With 7 upcoming biotech catalysts, including Deramiocel on August 22, investors should closely monitor these pivotal moments....
FDA & PDUFA Calendar
FDA Calendar August 2026: Key PDUFA Dates and Analysis
August 2026's FDA calendar spotlights critical PDUFA dates, including DTX401 and Deramiocel, each promising significant advances in their respective fields....
FDA & PDUFA Calendar
Tiziana Foralumab in MS: Catalysts Jul 27 2026
In 2026, 4 biotech catalysts to watch are poised to impact the market, including TLSA's Foralumab and CLDI's CLD-401. Key dates and insights inside....
FDA & PDUFA Calendar
Outlook LYTENAVA for nAMD: Catalysts Jul 20 2026
On July 20, 2026, we highlight 4 biotech catalysts with varying probabilities of approval, including OTLK's ONS-5010 and TLSA's foralumab....